Editas Medicine Inc (EDIT NASDAQ) stock market data APIs
$2.7018
0.08(3%)
as of September 17, 2025
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Price chart is built with
Anychart
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
2.7018
Open
2.7862
High
2.8738
Low
2.7163
52 wk Range
0.9101-3.89
Market Cap
254 M
Shares Outstanding
89 920 K
Revenue
38 901 K
EPS
-0.63
Beta
2.162
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Editas Medicine Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 38 901 K
- EBITDA: -154 068 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 16.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue le...
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
Editas Medicine EDIT has nominated EDIT-401 as its lead in vivo development candidate. The experimental, one-time gene editing therapy is designed to significantly reduce LDL cholesterol (LDL-C) level...
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into ...
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
